Alcobra Ltd. (“Alcobra” or the “Company”) is a pharmaceutical company that develops and commercializes new medications for CNS disorders including ADHD and Fragile X Syndrome.

According to the Complaint, this action stems from a Proposed Transaction announced on September 27, 2017, pursuant to which Alcobra will merge with Arcturus Therapeutics, Inc. in an all-stock transaction.

On September 27, 2017, Alcobra’s Board of Directors caused the Company to enter into an agreement and plan of merger with Arcturus and Aleph Mergersub Inc.

On September 28, 2017, Alcobra filed two Form 6-Ks with the United States Securities and Exchange Commission in connection with the Proposed Transaction. To date, Alcobra has not filed a Proxy Statement or proxy card with the SEC in connection with the Proposed Transaction, and Plaintiff has not received a Proxy Statement or proxy card by mail. Accordingly, Plaintiff seeks to enjoin the November 2, 2017 Stockholder Vote on the Proposed Transaction, as stockholders cannot make an informed decision with respect to the merger without a Proxy Statement.

On October 25, 2017, this case was voluntarily dismissed.